KCT0007090
Not yet recruiting
未知
Evaluation of the safety, efficacy, and economic evaluation of complex chuna treatment versus simple chuna treatment for non-acute low back pain accompanied by pelvic deviation: randomized, accessor-blind, multicenter pilot clinical trial
Pusan National University Korean Medicine Hospital0 sites30 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Pusan National University Korean Medicine Hospital
- Enrollment
- 30
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion criteria
- •1\. patient having pelvic deviation with non\-acute low back pain(onset before more than 2 weeks) and Numeric Rating Scale score above 5
- •2\. patient who has been confirmed to have pelvic deviation by manual diagnose of Korean Medicine dictor using X\-ray
- •3\. aged above 19 and below 65
- •4\. patient who is capable of ordinary communication
- •5\. participant who has signed the clinical trail consent form with voluntary participation decision
Exclusion Criteria
- •Exclusion criteria
- •1\. patient who is diagnosed with specific severe disease which could cause low back pain, or the cause of low back pain is not pelvic deviation (vertebral metastasis of tumor, acute fracture and dislocation, polio, etc.)
- •2\. 2\. patient with absolute contraindication of Chuna Manual Therapy(acute cauda equina syndrome, vertebral dislocation, cerebral aneurysm, etc.)
- •3\. patient who is considered inappropriate for the clinical trial by the staffs(e.g. lumbosacropelvic operation history, knee operation history, innate vertebral disease, nerve root block operation history, etc.)
- •4\. patient who has received Chuna Manual Therapy within a week, or taking medicine such as steroids, immunodepressant, mental disorder medicine, or other drugs which could affect study result(e.g.NSAIDs)
- •5\. operation or medical procedure is scheduled which could affect judgement of clinical trial result during the treatment period
- •6\. patient with chronic disease which could affect the effect of the clinical study : cardiovascular disease, kidney disease, diabetic neuropathy, dementia, epilepsy, etc.
- •7\. patient who has participated other clinical trials within 1 month
- •8\. patient who is incapable of ordinary communication because of dementia or mild cognition disorder, etc.
- •9\. pregnant women
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Evaluation of the safety, efficacy and cost-effectiveness of transcatheter tricuspid valve repair in patients with severe tricuspid regurgitation in the Netherlands.Severe Tricuspid valve Regurgitation (TR) - severe leaking right heart valve10046973NL-OMON53966Sint Antonius Ziekenhuis150
Completed
Not Applicable
The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer paiCancer painCancerISRCTN17751043Chinese association for the study of pain, the minimally invasive interventional group240
Recruiting
Not Applicable
Evaluation of the safety, effectiveness and natural care approach of the Jauni phototherapy romper.icterusJaundice10019654NL-OMON56682Erasmus MC, Universitair Medisch Centrum Rotterdam12
Not yet recruiting
Phase 3
The study evaluating the efficacy, safety and economic evaluation of Thai medical marijuana productsEfficacy and safety of 2 different Thai medical marijuana products compared to placebo in palliative care patientsEconomic cost and benefit of Thai marijuana productsMarijuanaCBDTHCCannabinoidCannabidolCanabisPalliativeSupportiveAdvance-stageMetastasisCancer.TCTR20210712003Dr. Pongtorn Chantharatsami668
Active, not recruiting
Phase 1
Evaluation of the therapeutic potential of a low-dose therapy with the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus.Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies.MedDRA version: 18.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 18.0Level: PTClassification code 10067657Term: Systemic lupus erythematosus disease activity index increasedSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2013-001599-40-DECharité - Universitätsmedizin Berlin12